Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

How Many Chronic Myeloid Leukemia (CML) Patients in Chronic Phase (CP) Benefit from Treatment Free Remission? a Single Center Real-Life Experience

Mariella D'Adda, Valeria Cancelli, Sofia Terlizzi, Annamaria Pelizzari, Samantha Ferrari, Diego Bertoli, Chiara Bottelli, Nicola Bianchetti, Annalisa Peli, Ilaria Accarino, Carlotta Giupponi, Alessandra Tucci

Blood (2024) 144 (Supplement 1): 6612.

https://doi.org/10.1182/blood-2024-210714

Published: 2024

Journal Articles

Early Identification of Functional High Risk Multiple Myeloma Patients after Transplant with Diffusion-Weighted Whole-Body MRI: Predictive Role of Fat Fraction in Addition to RAC Score

Angelo Belotti, Barbara Frittoli, Sofia Terlizzi, Rossella Ribolla, Claudia Crippa, Chiara Saeli, Samantha Ferrari, Annalisa Peli, Nicola Bianchetti, Chiara Bottelli, Chiara Cattaneo, Carmela Carbone, Alessandro Gullino, Marco Chiarini, Viviana Giustini, Aldo Roccaro, Luigi Grazioli, Alessandra Tucci

Blood (2024) 144 (Supplement 1): 82.

https://doi.org/10.1182/blood-2024-198779

Published: 2024

Journal Articles

Rituximab and Lenalidomide (R 2 ) Vs Rituximab Alone As Maintenance Treatment after Chemoimmunotherapy for Elderly Patients with Relapsed/Refractory Follicular Lymphoma (FL): Final Analysis of Renoir Phase III Study of the Fondazione Italiana Linfomi (FIL)

Blood (2023) 142 (Supplement 1): 982.

https://doi.org/10.1182/blood-2023-174901

Published: 2023

Journal Articles

Comparison between R-COMP and R-CHOP in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Substudy of the Elderly Project By the Fondazione Italiana Linfomi

Blood (2021) 138 (Supplement 1): 2487.

https://doi.org/10.1182/blood-2021-150337

Published: 2021

Journal Articles

Sustained Residual Disease Negativity Assessed By Diffusion-Weighted Whole-Body MRI (DW-MRI) Has Strong Predictive Relevance for Survival in Newly Diagnosed Multiple Myeloma Patients on Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT)

Angelo Belotti, Rossella Ribolla, Alberta Villanacci, Marco Chiarini, Viviana Giustini, Giulia Vittoria Facchetti, Claudia Crippa, Valeria Cancelli, Samantha Ferrari, Annalisa Peli, Chiara Bottelli, Chiara Cattaneo, Chiara Saeli, Aldo M. Roccaro, Luigi Grazioli, Giuseppe Rossi, Alessandra Tucci

Blood (2021) 138 (Supplement 1): 1641.

https://doi.org/10.1182/blood-2021-147694

Published: 2021

Journal Articles

Prognostic Factors for Developing Thrombosis in Polycytemia Vera: A Retrospective Analysis of 331 Patients with Long-Term Follow-up Highlights the Importance of White Blood Cells Levels

Samantha Ferrari, MD, Chiara Pagani, MD, Mariella D'Adda, MD, Nicola Bianchetti, MD, Annamaria Pelizzari, MD, Doriana Gramegna, MD, Chiara Bottelli, MD, Luisa Lorenzi, MD, Gabriella Vona, Alessandra Tucci, MD, Giuseppe Rossi, MD

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-139431

Published: 2020

Journal Articles

Definition and Validation of the New Elderly Prognostic Index (EPI) for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Geriatric and Clinical Assessment: Results of the Prospective "Elderly Project" on 1353 Patients By the Fondazione Italiana Linfomi

Blood (2019) 134 (Supplement_1): 398.

https://doi.org/10.1182/blood-2019-123027

Published: 2019

Journal Articles

R-Interferon Treatment before Imatinib Reverses the Negative Impact of e13a2 Transcript Type on Treatment Free Remission Duration after Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia Patients

Mariella D'Adda, MD, Mirko Farina, MD, Angela Passi, MD, Rosa Daffini, MD, Doriana Gramegna, MD, Elisa Cerqui, MD, Samantha Ferrari, MD, Chiara Bottelli, MD, Chiara Pagani, MD, Erika Borlenghi, MD, Diego Bertoli, PhD, Silvana Archetti, PhD, Mirella Marini, MD, Giuseppe Rossi

Blood (2019) 134 (Supplement_1): 4146.

https://doi.org/10.1182/blood-2019-125313

Published: 2019

Journal Articles

Potentially Cured Follicular Lymphoma (PC-FL). an Analysis of 56 Cases with Prognostic Factors Evaluation

Samantha Ferrari, MD, Alessandra Tucci, Gloria Valimberti, MD, Antonella Anastasia, MD, Chiara Bottelli, MD, Marta Petullà, Marina Motta, MD, Angela Passi, MD, Giuseppe Rossi, MD

Blood (2018) 132 (Supplement 1): 5328.

https://doi.org/10.1182/blood-2018-99-114896

Published: 2018

Journal Articles

The IMWG Frailty Score and Age Can be More Effective Than Clinical Judgement in the Selection of Elderly Patients with Newly Diagnosed Multiple Myeloma Who Can Benefit from an Intensive Treatment Approach with High Dose Melphalan and Autologous Stem Cell Transplantation

Angelo Belotti, MD, Rossella Ribolla, Valeria Cancelli, MD, Nicola Bianchetti, Claudia Crippa, MD, Samantha Ferrari, MD, Chiara Bottelli, MD, Chiara Cattaneo, MD, Vincenza Orlando, PharmD, Marco Chiarini, Luigi Grazioli, MD, Giuseppe Rossi

Blood (2018) 132 (Supplement 1): 2151.

https://doi.org/10.1182/blood-2018-99-113022

Published: 2018

Journal Articles

Bortezomib-Based Induction Regimen Followed By Autologous Stem Cell Transplantation (ASCT) after Conditioning with MEL200 Is Highly Effective and Well Tolerated in Elderly Multiple Myeloma (MM) Patients up to the Age of 75 Years

Angelo Belotti, MD, Rossella Ribolla, MD, Claudia Crippa, MD, Chiara Cattaneo, MD, Enrico Morello, MD, Vincenza Orlando, PharmD, Nicola Bianchetti, MD, Samantha Ferrari, MD, Chiara Bottelli, MD, Francesca Schieppati, MD, Aldo M. Roccaro, Marco Chiarini, Mario Morone, MD, Giuseppe Rossi, MD

Blood (2017) 130 (Supplement 1): 3161.

https://doi.org/10.1182/blood.V130.Suppl_1.3161.3161

Published: 2017

Journal Articles

Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) As First-Line Treatment in Patients with Double-Hit Lymphoma: Preliminary Results in 35 Consecutive Patients from Two Institutions

Alessandra Tucci, MD, Anna Guidetti, MD, Anna Dodero, MD, Francesca Schieppati, MD, Alessandro Re, MD, Nicola Bianchetti, MD, Chiara Bottelli, MD, Angela Passi, MD, Maria Miscio, Simona Fisogni, MD, Piera Balzarini, Fabio Facchetti, MD, Paolo Corradini, MD, Giuseppe Rossi, MD

Blood (2017) 130 (Supplement 1): 4154.

https://doi.org/10.1182/blood.V130.Suppl_1.4154.4154

Published: 2017

Journal Articles

An e13a2 Type of BCR-ABL Transcript Has a Significant Adverse Impact on the Achievement of a Sustained Deep Molecular Response and on the Maintenance of a Treatment Free Remission after Stopping Tyrosine Kinase Inhibitors

Mariella D'adda, Mirko Farina, MD, Francesca Schieppati, MD, Elisa Cerqui, MD, Giuseppina Ruggeri, MD, Samantha Ferrari, MD, Chiara Bottelli, MD, Chiara Pagani, MD, Angela Passi, MD, Giuseppe Rossi, MD

Blood (2017) 130 (Supplement 1): 1589.

https://doi.org/10.1182/blood.V130.Suppl_1.1589.1589

Published: 2017

Journal Articles

In Elderly Patients with CML Second Generation TKIs Are Very Effective and Can be Given Long Term Particularly in the Absence of Comorbidities: A Single Center Experience

Mariella D'Adda, MD, Elisa Cerqui, MD, Samantha Ferrari, MD, Chiara Bottelli, MD, Angela Passi, MD, Francesca Schieppati, MD, Rosaria Scaduto, Giuseppe Rossi, MD

Blood (2016) 128 (22): 5455.

https://doi.org/10.1182/blood.V128.22.5455.5455

Published: 2016

Journal Articles

LONG-TERM Outcome of a Fondazione Italiana Linfomi Study Comparing Short Rituximab Maintenance Vs Observation after Brief First-LINE R-FND Chemoimmunotherapy Followed By Rituximab Consolidation in Elderly Patients with Advanced Follicular Lymphoma (FL)

Blood (2015) 126 (23): 3985.

https://doi.org/10.1182/blood.V126.23.3985.3985

Published: 2015

Journal Articles

What Is the Best Combination of First-Line and Salvage Treatments in Follicular Lymphoma? Results of the Multicenter Study “Refoll” by the Fondazione Italiana Linfomi (FIL) On 548 Patients

Blood (2012) 120 (21): 154.

https://doi.org/10.1182/blood.V120.21.154.154

Published: 2012

Journal Articles

Rituximab-CHOP21 Plus Lenalidomide (LR-CHOP21) Is Effective and Feasible in Elderly Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of Phase II REAL07 Study of the Fondazione Italiana Linfomi (FIL)

Blood (2012) 120 (21): 903.

https://doi.org/10.1182/blood.V120.21.903.903

Published: 2012

Journal Articles

Prolonged Survival with Low Incidence of CNS Relapse and Late Toxicities in a Retrospective Series of 278 Young Patients with High-Risk (aa-IPI 2–3) Diffuse Large B-Cell Lymphoma Treated with Intensified Chemotherapy with or without Rituximab At Diagnosis

Blood (2011) 118 (21): 1606.

https://doi.org/10.1182/blood.V118.21.1606.1606

Published: 2011

Journal Articles

Salvage Treatment with Lenalidomide and Dexamethasone In Patients with Relapsed Refractory Mantle Cell Lymphoma: Clinical Results and Modifications of Angiogenic Biomarkers

Blood (2010) 116 (21): 966.

https://doi.org/10.1182/blood.V116.21.966.966

Published: 2010

Journal Articles

Association of Hodgkin Lymphoma and Non-Hodgkin Lymphoma In the Same Patient. Clinicopathologic Characteristics and Outcome In a Series of 20 Cases

Stefano Fogazzi, Alessandra Tucci, Chiara Bottelli, Marco Ungari, Fabio Facchetti, Giuseppe Rossi, MD

Blood (2010) 116 (21): 3886.

https://doi.org/10.1182/blood.V116.21.3886.3886

Published: 2010

NARROW

How Many Chronic Myeloid Leukemia (CML) Patients in Chronic Phase (CP) Benefit from Treatment Free Remission? a Single Center Real-Life Experience

Early Identification of Functional High Risk Multiple Myeloma Patients after Transplant with Diffusion-Weighted Whole-Body MRI: Predictive Role of Fat Fraction in Addition to RAC Score

Rituximab and Lenalidomide (R 2 ) Vs Rituximab Alone As Maintenance Treatment after Chemoimmunotherapy for Elderly Patients with Relapsed/Refractory Follicular Lymphoma (FL): Final Analysis of Renoir Phase III Study of the Fondazione Italiana Linfomi (FIL)

Comparison between R-COMP and R-CHOP in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Substudy of the Elderly Project By the Fondazione Italiana Linfomi

Sustained Residual Disease Negativity Assessed By Diffusion-Weighted Whole-Body MRI (DW-MRI) Has Strong Predictive Relevance for Survival in Newly Diagnosed Multiple Myeloma Patients on Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT)

Prognostic Factors for Developing Thrombosis in Polycytemia Vera: A Retrospective Analysis of 331 Patients with Long-Term Follow-up Highlights the Importance of White Blood Cells Levels

Definition and Validation of the New Elderly Prognostic Index (EPI) for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Geriatric and Clinical Assessment: Results of the Prospective "Elderly Project" on 1353 Patients By the Fondazione Italiana Linfomi

R-Interferon Treatment before Imatinib Reverses the Negative Impact of e13a2 Transcript Type on Treatment Free Remission Duration after Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia Patients

Potentially Cured Follicular Lymphoma (PC-FL). an Analysis of 56 Cases with Prognostic Factors Evaluation

The IMWG Frailty Score and Age Can be More Effective Than Clinical Judgement in the Selection of Elderly Patients with Newly Diagnosed Multiple Myeloma Who Can Benefit from an Intensive Treatment Approach with High Dose Melphalan and Autologous Stem Cell Transplantation

Bortezomib-Based Induction Regimen Followed By Autologous Stem Cell Transplantation (ASCT) after Conditioning with MEL200 Is Highly Effective and Well Tolerated in Elderly Multiple Myeloma (MM) Patients up to the Age of 75 Years

Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) As First-Line Treatment in Patients with Double-Hit Lymphoma: Preliminary Results in 35 Consecutive Patients from Two Institutions

An e13a2 Type of BCR-ABL Transcript Has a Significant Adverse Impact on the Achievement of a Sustained Deep Molecular Response and on the Maintenance of a Treatment Free Remission after Stopping Tyrosine Kinase Inhibitors

In Elderly Patients with CML Second Generation TKIs Are Very Effective and Can be Given Long Term Particularly in the Absence of Comorbidities: A Single Center Experience

LONG-TERM Outcome of a Fondazione Italiana Linfomi Study Comparing Short Rituximab Maintenance Vs Observation after Brief First-LINE R-FND Chemoimmunotherapy Followed By Rituximab Consolidation in Elderly Patients with Advanced Follicular Lymphoma (FL)

What Is the Best Combination of First-Line and Salvage Treatments in Follicular Lymphoma? Results of the Multicenter Study “Refoll” by the Fondazione Italiana Linfomi (FIL) On 548 Patients

Rituximab-CHOP21 Plus Lenalidomide (LR-CHOP21) Is Effective and Feasible in Elderly Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of Phase II REAL07 Study of the Fondazione Italiana Linfomi (FIL)

Prolonged Survival with Low Incidence of CNS Relapse and Late Toxicities in a Retrospective Series of 278 Young Patients with High-Risk (aa-IPI 2–3) Diffuse Large B-Cell Lymphoma Treated with Intensified Chemotherapy with or without Rituximab At Diagnosis

Salvage Treatment with Lenalidomide and Dexamethasone In Patients with Relapsed Refractory Mantle Cell Lymphoma: Clinical Results and Modifications of Angiogenic Biomarkers

Association of Hodgkin Lymphoma and Non-Hodgkin Lymphoma In the Same Patient. Clinicopathologic Characteristics and Outcome In a Series of 20 Cases

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only